CVAC
Price:
$2.74
Market Cap:
$554.24M
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phas...[Read more]
Industry
Biotechnology
IPO Date
2020-08-14
Stock Exchange
NASDAQ
Ticker
CVAC
According to CureVac N.V.’s latest financial reports and current stock price. The company's current Enterprise Value is 390.67M. This represents a change of -35.19% compared to the average of 602.76M of the last 4 quarters.
The mean historical Enterprise Value of CureVac N.V. over the last ten years is 5.22B. The current 390.67M Enterprise Value has changed 648.43% with respect to the historical average. Over the past ten years (40 quarters), CVAC's Enterprise Value was at its highest in in the March 2021 quarter at 15.67B. The Enterprise Value was at its lowest in in the September 2019 quarter at 0.
Average
5.22B
Median
6.15B
Minimum
480.18M
Maximum
9.37B
Discovering the peaks and valleys of CureVac N.V. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 9.46%
Maximum Annual Enterprise Value = 9.37B
Minimum Annual Increase = -87.35%
Minimum Annual Enterprise Value = 480.18M
Year | Enterprise Value | Change |
---|---|---|
2023 | 480.18M | -21.42% |
2022 | 611.05M | -87.35% |
2021 | 4.83B | -35.40% |
2020 | 7.48B | -20.17% |
2019 | 9.37B | 9.46% |
The current Enterprise Value of CureVac N.V. (CVAC) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
1.97B
5-year avg
4.55B
10-year avg
5.22B
CureVac N.V.’s Enterprise Value is
Company | Enterprise Value | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like CureVac N.V. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like CureVac N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is CureVac N.V.'s Enterprise Value?
What is the highest Enterprise Value for CureVac N.V. (CVAC)?
What is the 3-year average Enterprise Value for CureVac N.V. (CVAC)?
What is the 5-year average Enterprise Value for CureVac N.V. (CVAC)?
How does the current Enterprise Value for CureVac N.V. (CVAC) compare to its historical average?